Dark

Check out our API

NLSP
NLS Pharmaceutics Ltd.
stock NASDAQ

Inactive

Oct 30, 2025

7.62USD+2.973%(+0.22)4,762,465

Pre-market

0.00USD-100.000%(-7.40)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 4, 2022

07:46AM EST NLS Pharmaceutics Announced Patent Issuance in the United States for Its Mazindol Extended-release Formulation Benzinga

Dec 28, 2021

02:02PM EST NLS Pharmaceutics Granted US Patent 'MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)' Benzinga

Dec 20, 2021

04:12PM EST NLS Pharma Filing Shows Registration For ~1.47M Share Common Stock Offer Via Selling Shareholders Benzinga

Nov 30, 2021

04:48PM EST NLS Pharmaceutics Announces Preclinical Results From Study Of NLS-4 For Circadian Rhythm Dysregulation And Chronic Fatigue Syndrome In Long-Covid Model Benzinga

Nov 1, 2021

08:19AM EDT NLS Pharmaceutics CEO Issues Letter To Shareholders (Full Letter In Body) Benzinga

Oct 14, 2021

08:35AM EDT NLS Pharmaceutics Announces Preclinical Data Demonstrating Potential Of NLS-4 In Chronic Fatigue Associated With Long-COVID Benzinga

Sep 30, 2021

08:18AM EDT NLS Pharmaceutics To Participate In The Micro Cap Rodeo Fall Harvest Conference: Best Ideas From The Buy-Side Event Oct. 5 Benzinga

Sep 29, 2021

01:59PM EDT From BZ's Small Cap Healthcare Conference: NLS Pharmaceuticals Co-Founder & CEO, Alexander Zwyer Begins Speaking Benzinga

Sep 28, 2021

08:33AM EDT NLS Pharma 6-K Shows Co. Entered Standby Equity Distribution Deal With YA II PN Ltd: Co. Will Be Able To Sell Up To $20M In Common Shares At Co.'s Option During 3-Year Period Benzinga

Sep 14, 2021

08:44AM EDT NLS Initiates Phase 2 Trial For Quilience In Narcolepsy And Announces First Patient Enrolled Benzinga

Aug 20, 2021

06:03AM EDT Pre-market Movers: GOVX, PROG, SONN, MRIN, RTTNews

Aug 19, 2021

03:43PM EDT NLS Pharmaceuticals shares were trading higher after the company announced it received a Notice of Allowance for its US patent application covering its proprietary mazindol formulation. Benzinga

11:21AM EDT EXCLUSIVE: NLS Pharma CEO Comments On Notice Of Allowance For U.S. Patent Application Covering Its Proprietary Mazindol Formulation, Tells Benzinga Co. Remains 'on track to initiate our prospective Phase 2 clinical study for Quilience' Benzinga

07:54AM EDT NLS Pharmaceutics Announces Notice Of Allowance For US Patent Application Covering Its Proprietary Mazindol Formulation Benzinga

Jul 15, 2021

12:53PM EDT NLS Pharmaceutics shares were trading higher after the company announced the FDA has accepted its Investigational IND for Quilience for the treatment of narcolepsy. Benzinga

10:21AM EDT Shares of Swiss clinical-stage pharmaceutical company NLS Pharmaceutics AG (NLSP) are climbing more than 4% Thursday morning. RTTNews

Jun 2, 2021

08:02AM EDT NLS Pharmaceutics to Present at the LD Micro Virtual Invitational Conference on PR Newswire

May 28, 2021

08:15AM EDT NLS Pharmaceutics to Present at The MicroCap Rodeo 2021 Summer Solstice: Best PR Newswire

May 18, 2021

01:29PM EDT New Study Data Confirms NLS Pharmaceutics' Mazindol Orexin Pathway Activation For Sleeping Disorder Benzinga

08:17AM EDT NLS Pharmaceutics Announces New Study Data Confirming Mazindol's 'Unique Orexin Pathway Activation for Treating Narcolepsy' Benzinga

08:16AM EDT NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin PR Newswire

May 5, 2021

08:34AM EDT NLS Pharma Reports Patent Issued In Europe For Its Mazindol Controlled-Release Formulation Benzinga

May 3, 2021

11:11AM EDT NLS Pharma European Patent Office Abstract For Co.'s 'A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)' Benzinga

Apr 5, 2021

08:36AM EDT NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer Benzinga

08:35AM EDT NLS Pharmaceutics Appoints Silvia Panigone COO RTTNews

08:30AM EDT NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer PR Newswire

Mar 29, 2021

08:46AM EDT NLS Pharmaceutics Reports Issuance Of Canadian Patent Covering Novel Formulation Of Controlled-Release Mazindol RTTNews

08:41AM EDT NLS Pharmaceutics Announces Issuance Of Canadian Patent Covering Its Novel Formulation Of Controlled-Release Mazindol (Mazindol CR) Benzinga

08:30AM EDT NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel PR Newswire

Mar 12, 2021

02:42PM EST Mid-Afternoon Market Update: Dow Surges Over 200 Points; Prometheus Biosciences Shares Spike Higher Benzinga

12:11PM EST Mid-Day Market Update: Evoke Pharma Falls Following Q4 Earnings; NLS Pharmaceutics Shares Climb Benzinga

12:03PM EST Brookline Capital Initiates Coverage On NLS Pharmaceutics with Buy Rating, Announces Price Target of $12 Benzinga

10:13AM EST Mid-Morning Market Update: Markets Mixed; Buckle Earnings Top Views Benzinga

09:59AM EST NLS Pharmaceutics Stock Surges On Obesity Drug Licensing Pact With Novartis Pharma Benzinga

08:02AM EST NLS Pharma Reports Obtained License To Full Regulatory Data Package, Proprietary Know-How For Sanorex Benzinga

08:00AM EST NLS Pharmaceutics Obtains License to Full Regulatory Data Package and PR Newswire

Mar 10, 2021

04:24PM EST NLS Pharma 6-K Shows Co. Dismissed Its Independent Registered Public Accounting Firm, Engaged PricewaterhouseCoopers Benzinga

Mar 3, 2021

08:37AM EST Maxim Group Initiates Coverage On NLS Pharmaceutics with Buy Rating, Announces Price Target of $8 Benzinga

08:11AM EST NLS Pharma Shares Higher In Pre-Market Action As Hearing Maxim Initiated Coverage With A Buy Rating, $8 Price Target Benzinga

Feb 25, 2021

09:02AM EST NLS Pharmaceutics to Participate in Upcoming Investor Conferences PR Newswire

Feb 3, 2021

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

Feb 2, 2021

04:00PM EST NLS Pharmaceutics Ltd. Announces Closing of $20.0 Million Initial Public PR Newswire

08:05AM EST The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment Benzinga

Jan 28, 2021

07:55PM EST NLS Pharma Prices IPO Of 4.82 Mln Units At $4.15/unit RTTNews

07:30PM EST NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public PR Newswire

Share